Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Infertility
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Infertility
    TopAbstracts in Infertility 11/17/2009 - (DGNews)
    Fertility Procedures Need Not Delay Breast Cancer Treatment for Younger Women - (DGNews)
    Male Factor Infertility Associated With Comorbidities - (DGNews)
    Normal Spermatogenesis in a Man with Mutant Luteinizing Hormone - (N Engl J Med)
    Immobilisation versus immediate mobilisation after intrauterine insemination: randomised controlled trial - (BMJ)

    News archive

     Recent webcasts/CME - Infertility
      Luteal Support in Reproduction
      Reducing the Risks Associated with In Vitro Fertilization

      Webcasts/CME archive

       Recent cases - Infertility
        Osseous Metaplasia of the Endometrium Associated with Infertility: A Case Report and Review of the Literature
        Male Infertility Related to an Aberrant Karyotype 47,XYY: Four Case Reports
        Secondary Infertility Caused by the Retention of Fetal Bones After Abortion: A Case Report
        Resolution of Male Infertility Following Anti-Tumor Necrosis Factor (Infliximab): A Case Report
        First Successful Case of In Vitro Fertilization-Embryo Transfer with Venom Immunotherapy for Hymenoptera Sting Allergy

        Cases archive
          




        my personal edition > infertility > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Gonadotropin Releasing Hormone Agonist, Antagonist Show Similar Efficacy In Ovarian Stimulation: Presented at ASRM

        By Robert H. Carlson

        SAN ANTONIO, TX -- October 16, 2003 -- Infertile women who are treated with controlled ovarian stimulation with a gonadotropin releasing hormone (GnRH) antagonist have equivalent rates of embryo and clinical pregnancy compared with women who have stimulation with a GnRH agonist, according to a study from two large Mexican fertility clinics.

        The results of the study comparing the GnRH antagonist Antagon (called Orgalutran in Latin America) against the GnRH agonist Lupron were presented here October 13th at the 59th Annual Meeting of the American Society for Reproductive Medicine.

        Efrain Perez Pena, MD, director, Vida Institute of Human Reproductive Sciences, Guadalajara, Mexico, said no statistical differences were observed with either drug in terms of clinical pregnancy rates, implantation rates, number of deliveries or number of miscarriages.

        During the period from July 2001 through February 2002, 38.5% of 39 women taking Antagon gave birth compared with 32.4% of 37 women on Lupron. The number of miscarriages was 2.6% and 5.4%, respectively.

        Dr. Perez Pena added the GnRH antagonist allowed for a more convenient treatment schedule since injections are given for only 11 days of the woman's cycle, compared with 28 days for the GnRH agonist.

        Study co-author Arturo Garza Morales, MD, director, Vida Clinic, Matamoros, Mexico, said fewer injections would also make the antagonist treatment less expensive.

        In a separate study, researchers from Argentina Orgalutran Study Group reported that the GnRH antagonist could be used successfully in a short, safe and flexible program when combined with follitropin-beta (Puregon). The regimen was used for ovarian hyperstimulation in 132 women preparing for in-vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

        The regimen optimised patient convenience and resulted in good clinical outcomes, the authors noted.


        [Study title: Quality Embryo and Pregnancy Clinical in Women Undergoing Controlled Ovarian Stimulation with GnRH agonist versus Antagonist. Abstract P-538]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send